RIGEL PHARMACEUTICALS INC's ticker is RIGL and the CUSIP is 766559603. A total of 98 filers reported holding RIGEL PHARMACEUTICALS INC in Q3 2013. The put-call ratio across all filers is 0.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2016 | $5,199,000 | +4.2% | 2,331,366 | -2.8% | 0.20% | -3.8% |
Q1 2016 | $4,988,000 | -31.4% | 2,397,855 | 0.0% | 0.21% | -27.9% |
Q4 2015 | $7,266,000 | +22.7% | 2,397,855 | 0.0% | 0.29% | +28.4% |
Q3 2015 | $5,923,000 | -23.0% | 2,397,855 | 0.0% | 0.23% | -10.5% |
Q2 2015 | $7,697,000 | -10.1% | 2,397,855 | 0.0% | 0.26% | -7.6% |
Q1 2015 | $8,560,000 | +57.3% | 2,397,855 | 0.0% | 0.28% | +41.3% |
Q4 2014 | $5,443,000 | +17.0% | 2,397,855 | 0.0% | 0.20% | +15.3% |
Q3 2014 | $4,652,000 | -46.6% | 2,397,855 | 0.0% | 0.17% | -51.4% |
Q2 2014 | $8,704,000 | +118.4% | 2,397,855 | +133.4% | 0.35% | +114.7% |
Q1 2014 | $3,986,000 | +83.2% | 1,027,443 | +34.5% | 0.16% | +44.2% |
Q4 2013 | $2,176,000 | -43.1% | 763,675 | -28.5% | 0.11% | -36.5% |
Q3 2013 | $3,822,000 | -57.8% | 1,067,726 | -60.6% | 0.18% | -58.3% |
Q2 2013 | $9,052,000 | – | 2,710,053 | – | 0.43% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
CM Management, LLC | 1,500,000 | $1,620,000 | 1.72% |
Soleus Capital Management, L.P. | 14,803,015 | $15,987,256 | 1.48% |
ARMISTICE CAPITAL, LLC | 17,136,000 | $18,506,880 | 0.28% |
SPHERA FUNDS MANAGEMENT LTD. | 1,228,126 | $1,326,376 | 0.24% |
GSA CAPITAL PARTNERS LLP | 971,441 | $1,049 | 0.09% |
NJ State Employees Deferred Compensation Plan | 200,000 | $216,000 | 0.03% |
Providence Wealth Advisors, LLC | 27,500 | $29,013 | 0.03% |
XTX Topco Ltd | 164,238 | $177,377 | 0.03% |
JACOBS LEVY EQUITY MANAGEMENT, INC | 3,369,076 | $3,638,602 | 0.02% |
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 1,151,765 | $1,243,906 | 0.02% |